Claudio Borghi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1456291/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 2020, 75, 1334-1357.	1.3	1,895
2	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 3147-3197.	1.0	1,694
3	The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction. New England Journal of Medicine, 1995, 332, 80-85.	13.9	747
4	Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients. Circulation, 2009, 120, 1598-1605.	1.6	524
5	2020 International Society of Hypertension global hypertension practice guidelines. Journal of Hypertension, 2020, 38, 982-1004.	0.3	452
6	Serum uric acid and the risk of cardiovascular and renal disease. Journal of Hypertension, 2015, 33, 1729-1741.	0.3	366
7	Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. American Journal of Kidney Diseases, 2018, 71, 851-865.	2.1	362
8	Age and Multimorbidity Predict Death Among COVID-19 Patients. Hypertension, 2020, 76, 366-372.	1.3	330
9	Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. European Heart Journal, 2011, 32, 2143-2152.	1.0	285
10	Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects. Atherosclerosis, 2020, 292, 90-98.	0.4	213
11	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension, 2020, 75, 302-308.	1.3	177
12	May Measurement Month 2019. Hypertension, 2020, 76, 333-341.	1.3	157
13	Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. European Journal of Internal Medicine, 2020, 80, 1-11.	1.0	156
14	Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis. Journal of Hypertension, 2014, 32, 57-64.	0.3	141
15	Obesity and Cardiometabolic Risk Factors: From Childhood to Adulthood. Nutrients, 2021, 13, 4176.	1.7	135
16	Use of Statins and Blood Pressure Control in Treated Hypertensive Patients with Hypercholesterolemia. Journal of Cardiovascular Pharmacology, 2000, 35, 549-555.	0.8	133
17	ls it time to revise the normal range of serum uric acid levels?. European Review for Medical and Pharmacological Sciences, 2014, 18, 1295-306.	0.5	132
18	Evidence of a Partial Escape of Reninâ€Angiotensinâ€Aldosterone Blockade in Patients with Acute Myocardial Infarction Treated with Ace Inhibitors. Journal of Clinical Pharmacology, 1993, 33, 40-45.	1.0	122

#	Article	IF	CITATIONS
19	The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nature Reviews Nephrology, 2019, 15, 767-775.	4.1	122
20	Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. Journal of Human Hypertension, 2011, 25, 425-436.	1.0	119
21	Blood pressure control in Italy: results of recent surveys on hypertension. Journal of Hypertension, 2007, 25, 1491-1498.	0.3	117
22	Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. American Journal of Obstetrics and Gynecology, 2000, 183, 140-147.	0.7	116
23	Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. American Journal of Obstetrics and Gynecology, 2000, 183, 140-147.	0.7	116
24	Continuous Ultrafiltration for Congestive Heart Failure: The CUORE Trial. Journal of Cardiac Failure, 2014, 20, 9-17.	0.7	116
25	Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clinical Nutrition, 2020, 39, 1742-1752.	2.3	106
26	Uric Acid and Hypertension: An Update With Recommendations. American Journal of Hypertension, 2020, 33, 583-594.	1.0	104
27	Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. American Heart Journal, 2004, 148, 285-292.	1.2	102
28	Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial. European Journal of Nutrition, 2020, 59, 477-483.	1.8	102
29	Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management. Current Vascular Pharmacology, 2009, 7, 330-337.	0.8	101
30	Uric acid as a cross-over between rheumatology and cardiovascular disease. Current Medical Research and Opinion, 2013, 29, 1-2.	0.9	100
31	Do the Lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials. American Journal of Hypertension, 2013, 26, 442-449.	1.0	96
32	Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. International Journal of Cardiology, 2018, 261, 183-188.	0.8	95
33	Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. Critical Reviews in Food Science and Nutrition, 2019, 59, 1605-1618.	5.4	94
34	Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for) Tj ETQq(0.0 rgBT	/Oygrlock 10
	Survey of physiciansâ∈™ practices in the control of cardiovascular risk factors: the FLIDIKA study		

35	European Journal of Preventive Cardiology, 2012, 19, 541-550.	0.8	92
36	Nutraceuticals with a clinically detectable blood pressureâ€lowering effect: a review of available randomized clinical trials and their metaâ€analyses. British Journal of Clinical Pharmacology, 2017, 83, 163-171.	1.1	88

#	Article	IF	CITATIONS
37	Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovascular Disorders, 2017, 17, 160.	0.7	80
38	Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. American Journal of Hypertension, 1999, 12, 665-672.	1.0	78
39	Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Scientific Reports, 2018, 8, 11529.	1.6	78
40	Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. International Journal of Cardiology, 2016, 218, 83-88.	0.8	76
41	Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. American Heart Journal, 2003, 145, 80-87.	1.2	75
42	Different Effect of Psyllium and Guar Dietary Supplementation on Blood Pressure Control in Hypertensive Overweight Patients: A Six-Month, Randomized Clinical Trial. Clinical and Experimental Hypertension, 2007, 29, 383-394.	0.5	72
43	Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. RMD Open, 2021, 7, e001735.	1.8	72
44	High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. European Journal of Internal Medicine, 2017, 37, 38-42.	1.0	70
45	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. Journal of Hypertension, 2020, 38, 412-419.	0.3	70
46	Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial. European Journal of Nutrition, 2021, 60, 655-663.	1.8	67
47	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. Journal of the American Heart Association, 2017, 6, .	1.6	66
48	Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. Journal of Human Hypertension, 2017, 31, 258-262.	1.0	62
49	An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Vascular Health and Risk Management, 2017, Volume 13, 23-28.	1.0	62
50	Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 429-444.	1.0	61
51	Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. Mediterranean Journal of Nutrition and Metabolism, 2010, 3, 47-54.	0.2	60
52	Personalized medicine—a modern approach for the diagnosis and management of hypertension. Clinical Science, 2017, 131, 2671-2685.	1.8	59
53	2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 45-52.	1.0	57
54	Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension. Journal of Hypertension, 2019, 37, 728-731.	0.3	56

#	Article	IF	CITATIONS
55	Medication adherence in hypertension. Journal of Hypertension, 2020, 38, 579-587.	0.3	55
56	COVID-19-Related Quarantine Effect on Dietary Habits in a Northern Italian Rural Population: Data from the Brisighella Heart Study. Nutrients, 2021, 13, 309.	1.7	54
57	Systemic Hypotension and the Development of Acute Sensorineural Hearing Loss in Young Healthy Subjects. JAMA Otolaryngology, 2001, 127, 1049.	1.5	53
58	Uric acid and hypertension. Journal of Hypertension, 2019, 37, 878-883.	0.3	53
59	A Randomized Placebo-Controlled Clinical Trial to Evaluate the Medium-Term Effects of Oat Fibers on Human Health: The Beta-Clucan Effects on Lipid Profile, Clycemia and inTestinal Health (BELT) Study. Nutrients, 2020, 12, 686.	1.7	53
60	Interactions between hypercholesterolemia and hypertension: implications for therapy. Current Opinion in Nephrology and Hypertension, 2002, 11, 489-496.	1.0	52
61	Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study. Annals of Medicine, 2017, 49, 275-282.	1.5	52
62	Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiology Journal, 2018, 25, 545-563.	0.5	52
63	Relative role of systolic, diastolic and pulse pressure as risk factors for cardiovascular events in the Brisighella Heart Study. Journal of Hypertension, 2002, 20, 1737-1742.	0.3	51
64	Omega 3 Polyunsaturated Fatty Acids Supplementation and Blood Pressure Levels in Hypertriglyceridemic Patients with Untreated Normal-High Blood Pressure and With or Without Metabolic Syndrome: A Retrospective Study. Clinical and Experimental Hypertension, 2010, 32, 137-144.	0.5	51
65	Hyperuricemia and cardiovascular disease risk. Expert Review of Cardiovascular Therapy, 2014, 12, 1219-1225.	0.6	51
66	Serum Uric Acid and Cardiometabolic Disease. Hypertension, 2017, 69, 1011-1013.	1.3	51
67	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. PLoS ONE, 2020, 15, e0237297.	1.1	51
68	Urate-Lowering Drugs and Prevention of Cardiovascular Disease. Hypertension, 2016, 67, 496-498.	1.3	50
69	Nutrients and Nutraceuticals for the Management of High Normal Blood Pressure: An Evidence-Based Consensus Document. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 9-25.	1.0	50
70	Statins and blood pressure regulation. Current Hypertension Reports, 2001, 3, 281-288.	1.5	49
71	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 62-69.	0.3	49
72	Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Medical Principles and Practice, 2021, 30, 122-130.	1.1	48

#	Article	IF	CITATIONS
73	Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina (Lithuania), 2021, 57, 58.	0.8	48
74	Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000–2005 and 2005–2011 hypertension surveys. Journal of Human Hypertension, 2015, 29, 696-701.	1.0	47
75	Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study. International Journal of Cardiology, 2018, 253, 167-173.	0.8	47
76	Effects of nâ€3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. BioFactors, 2016, 42, 316-322.	2.6	47
77	Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. Annals of Hepatology, 2018, 17, 64-75.	0.6	46
78	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 171-180.	1.4	46
79	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 333-340.	0.3	46
80	Effects of zofenopril on myocardial ischemia in post–myocardial infarction patients with preserved left ventricular function: The Survival of Myocardial Infarction Long-term Evaluation (SMILE)–ISCHEMIA study. American Heart Journal, 2007, 153, 445.e7-445.e14.	1.2	45
81	Trends in Prevalence, Awareness, Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World Hypertension Day in Italy. Journal of Clinical Hypertension, 2016, 18, 551-556.	1.0	45
82	Prevalence of tinnitus in patients withhypertension and the impact of different anti hypertensive drugs on the incidence of tinnitus: A prospective, single-blind, observational study. Current Therapeutic Research, 2005, 66, 420-432.	0.5	44
83	LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: Data from the Brisighella Heart Study cohort. International Journal of Cardiology, 2018, 261, 204-208.	0.8	44
84	Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: Results from the Fosinopril in Acute Myocardial Infarction Study. American Heart Journal, 1998, 136, 213-225.	1.2	43
85	The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. Journal of Cardiovascular Medicine, 2019, 20, 631-639.	0.6	43
86	Nutraceuticals and blood pressure control: a European Society of Hypertension position document. Journal of Hypertension, 2020, 38, 799-812.	0.3	43
87	Trends in blood pressure control and antihypertensive treatment in clinical practice. Journal of Hypertension, 2004, 22, 1707-1716.	0.3	42
88	Effect of apple polyphenols on vascular oxidative stress and endothelium function: a translational study. Molecular Nutrition and Food Research, 2017, 61, 1700373.	1.5	42
89	Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. European Journal of Internal Medicine, 2017, 37, 49-55.	1.0	42
90	The Relationship Between Systolic Blood Pressure and Cardiovascular Risk?Results of the Brisighella Heart Study. Journal of Clinical Hypertension, 2003, 5, 47-52.	1.0	41

#	Article	IF	CITATIONS
91	Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. Hypertension Research, 2011, 34, 1035-1040.	1.5	40
92	The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. Current Hypertension Reports, 2017, 19, 95.	1.5	40
93	Effects of the Early ACE Inhibition in Diabetic Nonthrombolyzed Patients With Anterior Acute Myocardial Infarction. Diabetes Care, 2003, 26, 1862-1868.	4.3	39
94	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis, 2019, 285, 40-48.	0.4	39
95	Uric Acid Amplifies Al ² Amyloid Effects Involved in the Cognitive Dysfunction/Dementia: Evidences From an Experimental Model In Vitro. Journal of Cellular Physiology, 2017, 232, 1069-1078.	2.0	38
96	Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study. European Journal of Internal Medicine, 2018, 53, 29-33.	1.0	37
97	Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies. Drug Safety, 2020, 43, 727-736.	1.4	37
98	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 105-108.	1.0	37
99	Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiology Journal, 2021, 28, 1-14.	0.5	37
100	Early treatment of acute myocardlal infarction with anglotensin-convertlng enzyme inhibition: Safety considerations. American Journal of Cardiology, 1991, 68, 101-110.	0.7	36
101	Renin–angiotensin system at the crossroad of hypertension and hypercholesterolemia. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 115-120.	1.1	36
102	Uric acid is linked to cardiometabolic risk factors in overweight and obese youths. Journal of Hypertension, 2018, 36, 1840-1846.	0.3	36
103	Use of Lipidâ€Lowering Drugs and Blood Pressure Control in Patients With Arterial Hypertension. Journal of Clinical Hypertension, 2002, 4, 277-285.	1.0	35
104	Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort. European Journal of Internal Medicine, 2015, 26, 255-258.	1.0	35
105	A brief history of uric acid: From gout to cardiovascular risk factor. European Journal of Internal Medicine, 2015, 26, 373.	1.0	35
106	Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 197-202.	1.0	35
107	Comparison Between Zofenopril and Ramipril in Combination With Acetylsalicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a Randomized, Doubleâ€Blind, Parallelâ€Group, Multicenter, European Study (SMILEâ€4). Clinical Cardiology, 2012. 35. 416-423.	0.7	34
108	Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. Nutrition and Metabolism, 2017, 14, 61.	1.3	34

#	Article	IF	CITATIONS
109	Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 197-205.	1.1	34
110	Polypill, hypertension and medication adherence: The solution strategy?. International Journal of Cardiology, 2018, 252, 181-186.	0.8	34
111	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. Journal of Nephrology, 2022, 35, 211-221.	0.9	34
112	Lercanidipine in hypertension. Vascular Health and Risk Management, 2005, 1, 173-82.	1.0	34
113	A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opinion on Pharmacotherapy, 2004, 5, 1965-1977.	0.9	33
114	Leisure-time physical activity and cardiovascular disease mortality. Journal of Cardiovascular Medicine, 2012, 13, 559-564.	0.6	33
115	A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vascular Health and Risk Management, 2007, 3, 999-1005.	1.0	33
116	The Role of Uric Acid in Acute and Chronic Coronary Syndromes. Journal of Clinical Medicine, 2021, 10, 4750.	1.0	32
117	The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5519-5528.	1.8	31
118	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. Clinical Research in Cardiology, 2021, 110, 1073-1082.	1.5	31
119	Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences, 2016, 20, 983-92.	0.5	31
120	Effects of the Early Administration of Zofenopril on Onset and Progression of Congestive Heart Failure in Patients With Anterior Wall Acute Myocardial Infarction**This study was supported by a grant from Bristol-Myers Squibb Institute for Pharmaceutical Research, which was not involved in the acquisition or management of data and did not have access to unblinded information American	0.7	30
121	Serum cholesterol levels, blood pressure response to stress and incidence of stable hypertension in young subjects with high normal blood pressure. Journal of Hypertension, 2004, 22, 265-272.	0.3	30
122	Uricaemia and ejection fraction in elderly heart failure outpatients. European Journal of Clinical Investigation, 2014, 44, 573-577.	1.7	30
123	Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial. Archives of Medical Science, 2016, 3, 507-512.	0.4	30
124	Uric Acid and Hypertension: Prognostic Role and Guide for Treatment. Journal of Clinical Medicine, 2021, 10, 448.	1.0	30
125	Improved Tolerability of the Dihydropyridine Calcium-Channel Antagonist Lercanidipine: The Lercanidipine Challenge Trial. Blood Pressure, 2003, 12, 14-21.	0.7	29
126	Threeâ€arm, placeboâ€controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjects. Phytotherapy Research, 2019, 33, 2094-2101.	2.8	29

#	Article	IF	CITATIONS
127	MENIERE'S DISEASE: UPDATE OF ETIOPATHOGENETIC THEORIES AND PROPOSAL OF A POSSIBLE MODEL OF EXPLANATION. Acta Clinica Belgica, 2010, 65, 170-175.	0.5	28
128	From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the Brisighella Heart Study. Clinical Lipidology, 2011, 6, 269-276.	0.4	28
129	Arterial Stiffness, Sugar-Sweetened Beverages and Fruits Intake in a Rural Population Sample: Data from the Brisighella Heart Study. Nutrients, 2019, 11, 2674.	1.7	28
130	Hyperuricemia: a novel old disorder—relationship and potential mechanisms in heart failure. Heart Failure Reviews, 2020, 25, 43-51.	1.7	28
131	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal -	1.4	27
132	Cardiovascular Pharmacotherapy, 2020, 6, 86-95. Interaction between serum cholesterol levels and the renin–angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure. Journal of Hypertension, 2007, 25, 2051-2057.	0.3	26
133	Hemodynamic and neurohumoral profile in patients with different types of hypertension in pregnancy. Internal and Emergency Medicine, 2011, 6, 227-234.	1.0	26
134	Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. Internal and Emergency Medicine, 2013, 8, 265-267.	1.0	26
135	The role of uric acid in the development of cardiovascular disease. Current Medical Research and Opinion, 2015, 31, 1-2.	0.9	26
136	Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects. Therapeutics and Clinical Risk Management, 2016, 12, 281.	0.9	26
137	Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial. Advances in Therapy, 2017, 34, 1966-1975.	1.3	26
138	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2020, 190, 2226-2236.	1.9	26
139	Hypertension and Dyslipidemia Combined Therapeutic Approaches. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 221-230.	1.0	26
140	Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample. Journal of Hypertension, 2012, 30, 492-496.	0.3	25
141	Gender Difference in Hepatic Steatosis Index and Lipid Accumulation Product Ability to Predict Incident Metabolic Syndrome in the Historical Cohort of the Brisighella Heart Study. Metabolic Syndrome and Related Disorders, 2013, 11, 412-416.	0.5	25
142	Effect of Lactotripeptides (Isoleucine–Proline–Proline/Valine–Proline–Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical Trial. Metabolic Syndrome and Related Disorders, 2016, 14, 161-166.	0.5	25
143	Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?. Annals of Oncology, 2018, 29, 284-286.	0.6	25
144	Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. Internal and Emergency Medicine, 2019, 14, 949-956.	1.0	25

#	Article	IF	CITATIONS
145	Next Generation Sequencing for the Prediction of the Antibiotic Resistance in Helicobacter pylori: A Literature Review. Antibiotics, 2021, 10, 437.	1.5	25
146	The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems. Cardiology Clinics, 2021, 39, 365-376.	0.9	25
147	Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe. PLoS ONE, 2015, 10, e0115270.	1.1	25
148	Evidence of Clinically Relevant Efficacy for Dietary Supplements and Nutraceuticals. Current Hypertension Reports, 2013, 15, 260-267.	1.5	24
149	Beneficial Effects of Listening to Classical Music in Patients With Heart Failure: A Randomized Controlled Trial. Journal of Cardiac Failure, 2020, 26, 541-549.	0.7	24
150	Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 384-393.	1.4	24
151	Inner ear dysfunction of uncertain origin: A multidisciplinary approach could give something more. Medical Hypotheses, 2009, 72, 188-189.	0.8	23
152	Long-term Effect of a Dietary Education Program on Postmenopausal Cardiovascular Risk and Metabolic Syndrome: The Brisighella Heart Study. Journal of Women's Health, 2010, 19, 133-137.	1.5	23
153	Blood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice. Clinical and Experimental Hypertension, 2012, 34, 113-117.	0.5	23
154	Post-partum evaluation of maternal cardiac function after severe preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 696-701.	0.7	23
155	Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study. Internal and Emergency Medicine, 2014, 9, 655-660.	1.0	23
156	Effect of spontaneous changes in dietary components and lipoprotein(a) levels: Data from the Brisighella Heart Study. Atherosclerosis, 2017, 262, 202-204.	0.4	23
157	The management of hyperuricemia: back to the pathophysiology of uric acid. Current Medical Research and Opinion, 2017, 33, 1-4.	0.9	23
158	Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). BMC Public Health, 2010, 10, 382.	1.2	22
159	Tinnitus in elderly patients and prognosis of mild-to-moderate congestive heart failure: a cross-sectional study with a long-term extension of the clinical follow-up. BMC Medicine, 2011, 9, 80.	2.3	22
160	Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutrition Journal, 2015, 14, 30.	1.5	22
161	Maternal cardiac evaluation during uncomplicated twin pregnancy with emphasis on the diastolic function. American Journal of Obstetrics and Gynecology, 2015, 213, 376.e1-376.e8.	0.7	22
162	Hyperuricemia, urate deposition and the association with hypertension. Current Medical Research and Opinion, 2015, 31, 15-19.	0.9	22

#	Article	IF	CITATIONS
163	Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 13-18.	1.0	22
164	Palaeopathology of the earlobe crease (Frank's sign): New insights from Renaissance art. International Journal of Cardiology, 2017, 236, 82-84.	0.8	22
165	The Effect of Ketogenic Diet on Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review. Frontiers in Medicine, 2021, 8, 792846.	1.2	22
166	Effects of early angiotensin-converting enzyme inhibition in patients with non–ST-elevation acute anterior myocardial infarction. American Heart Journal, 2006, 152, 470-477.	1.2	21
167	The association between blood pressure and lipid levels in Europe. Journal of Hypertension, 2016, 34, 2155-2163.	0.3	21
168	Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 283-288.	1.0	21
169	Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (AMPERES) study. Current Medical Research and Opinion, 2018, 34, 1571-1577.	0.9	21
170	Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 5-11.	1.0	21
171	Evaluation of twelve formulas for LDL-C estimation in a large, blinded, random Italian population International Journal of Cardiology, 2021, 330, 221-227.	0.8	21
172	Post Acute Myocardial Infarction The Fosinopril in Acute Myocardial Infarction Study (FAMIS). American Journal of Hypertension, 1997, 10, 247S-254S.	1.0	20
173	Renal protection in chronic heart failure: focus on sacubitril/valsartan. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 445-452.	1.4	20
174	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. Journal of Human Hypertension, 2022, 36, 976-982.	1.0	20
175	Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension. Journal of Hypertension, 2021, 39, 376-380.	0.3	20
176	Renal Artery Denervation for Treating Resistant Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 237-244.	1.0	19
177	Long-term clinical experience with zofenopril. Expert Review of Cardiovascular Therapy, 2012, 10, 973-982.	0.6	19
178	Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Design, Development and Therapy, 2015, 9, 3073.	2.0	19
179	The Effect of Chorionicity on Maternal Cardiac Adaptation to Uncomplicated Twin Pregnancy: A Prospective Longitudinal Study. Fetal Diagnosis and Therapy, 2019, 45, 394-402.	0.6	19
180	Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease. American Journal of Cardiology, 2019, 123, 588-591.	0.7	19

#	Article	IF	CITATIONS
181	Antimicrobial Efficacy of Five Probiotic Strains Against Helicobacter pylori. Antibiotics, 2020, 9, 244.	1.5	19
182	Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2770-e2777.	1.8	19
183	Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3305-3313.	1.1	19
184	Zofenopril. Clinical Drug Investigation, 2000, 20, 371-384.	1.1	18
185	Persistence of Treatment and Blood Pressure Control in Elderly Hypertensive Patients Treated With Different Classes of Antihypertensive Drugs. The American Journal of Geriatric Cardiology, 2007, 16, 280-286.	0.7	18
186	Persistence on Treatment and Blood Pressure Control with Different First-Line Antihypertensive Treatments: A Prospective Evaluation. Clinical and Experimental Hypertension, 2007, 29, 553-562.	0.5	18
187	Direct Renin Inhibition. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 93-105.	1.0	18
188	Serum <scp>LDL</scp> cholesterol levels and new onset of arterial hypertension: an 8â€year followâ€up. European Journal of Clinical Investigation, 2014, 44, 926-932.	1.7	18
189	Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 759-766.	1.1	18
190	Elevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 361-368.	1.1	18
191	Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 527-529.	1.1	18
192	Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opinion on Pharmacotherapy, 2019, 20, 1277-1288.	0.9	18
193	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. Frontiers in Cardiovascular Medicine, 2021, 8, 713652.	1.1	18
194	Evidence-Based Medicine and ACE Inhibition. Journal of Cardiovascular Pharmacology, 1998, 32, S24-S35.	0.8	18
195	Uric Acid and Risk of Cardiovascular Disease: A Question of Start and Finish. Hypertension, 2021, 78, 1219-1221.	1.3	18
196	Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vascular Health and Risk Management, 2008, Volume 4, 665-671.	1.0	17
197	Zofenopril and incidence of cough: a review of published and unpublished data. Therapeutics and Clinical Risk Management, 2011, 7, 459.	0.9	17
198	Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: A 12-years follow-up of the Brisighella Heart Study historical cohort. Diabetes Research and Clinical Practice, 2014, 104, 183-188.	1.1	17

#	Article	IF	CITATIONS
199	Prevalence and Control of Hypertension in Different Macro-Areas in Italy: Analysis of a Large Database by the General Practice. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 387-393.	1.0	17
200	Cardiovascular risk and hypertension control in Italy. Data from the 2015 World Hypertension Day. International Journal of Cardiology, 2017, 243, 529-532.	0.8	17
201	Ferrari Corporate Wellness Program: Results of a Pilot Analysis and the "Drag―Impact in the Workplace. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 261-266.	1.0	17
202	Effect of quantitative and qualitative diet prescription on children behavior after diagnosis of heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2019, 293, 193-196.	0.8	17
203	Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction. Current Medical Research and Opinion, 2019, 35, 9-12.	0.9	17
204	Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine, 2020, 81, 50-53.	1.0	17
205	Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 406-419.	1.4	17
206	The older patient with hypertension: care and cure. Therapeutic Advances in Chronic Disease, 2012, 3, 231-236.	1.1	16
207	Kidney disease and inner ear impairment: a simpler and closer pathogenic analogy?. Internal and Emergency Medicine, 2012, 7, 93-95.	1.0	16
208	Rate of control of LDL cholesterol and incident hypertension requiring antihypertensive treatment in hypercholesterolemic subjects in daily clinical practice. Annals of Medicine, 2014, 46, 97-102.	1.5	16
209	Independent Determinants of Maternal and Fetal Outcomes in a Sample of Pregnant Outpatients With Normal Blood Pressure, Chronic Hypertension, Gestational Hypertension, and Preeclampsia. Journal of Clinical Hypertension, 2015, 17, 777-782.	1.0	16
210	Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study. Advances in Therapy, 2018, 35, 604-618.	1.3	16
211	Association Between the Serum Uric Acid Levels and Lacunar Infarcts in the Elderly. Journal of Molecular Neuroscience, 2018, 65, 385-390.	1.1	16
212	Nation-wide hypertension screening in Italy: data from May Measurements Month 2017—Europe. European Heart Journal Supplements, 2019, 21, D66-D70.	0.0	16
213	Emerging drugs for the treatment of hypercholesterolemia. Expert Opinion on Emerging Drugs, 2019, 24, 63-69.	1.0	16
214	Hyperuricaemia and vascular risk. Current Opinion in Cardiology, 2019, 34, 399-405.	0.8	16
215	Hyperuricemia and chronic kidney disease: to treat or not to treat. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 572-579	0.4	16
216	One year of SARS-CoV-2 and lung ultrasound: what has been learned and future perspectives. Journal of Ultrasound, 2021, 24, 115-123.	0.7	16

#	Article	IF	CITATIONS
217	Evidence-Based Medicine and ACE Inhibition. Journal of Cardiovascular Pharmacology, 1998, 32, S24-S35.	0.8	16
218	Impaired Vasodilator Capacity and Exaggerated Pressor Response to Isometric Exercise in Subjects with Family History of Hypertension. American Journal of Hypertension, 1988, 1, 106S-109S.	1.0	15
219	Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension. Clinical Drug Investigation, 2010, 30, 843-854.	1.1	15
220	Relationship Between Serum Uric Acid and Electrocardiographic Alterations in a Large Sample of General Population: Data From the Brisighella Heart Study. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 129-134.	1.0	15
221	Serum uric acid and acute coronary syndrome: Is there a role for functional markers of residual cardiovascular risk?. International Journal of Cardiology, 2018, 250, 62-63.	0.8	15
222	Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. Critical Reviews in Food Science and Nutrition, 2019, 59, 328-335.	5.4	15
223	Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction. IJC Heart and Vasculature, 2020, 31, 100656.	0.6	15
224	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1245-1252.	1.1	15
225	Possible role of HMG-CoA reductase inhibitors for the treatment of sudden sensorineural hearing loss (SSHL). Medical Hypotheses, 2002, 58, 399-402.	0.8	14
226	Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and Adherence, 2012, 6, 449.	0.8	14
227	Short-Term Hemodynamic Effects of Modern Wheat Products Substitution in Diet with Ancient Wheat Products: A Cross-Over, Randomized Clinical Trial. Nutrients, 2018, 10, 1666.	1.7	14
228	Application of the Sampson equation to estimate LDL-C in children: Comparison with LDL direct measurement and Friedewald equation in the BLIP study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1911-1915.	1.1	14
229	Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Longâ€ŧerm Evaluation trial. Fundamental and Clinical Pharmacology, 2009, 23, 641-648.	1.0	13
230	Association between self-reported snoring and arterial stiffness: data from the Brisighella Heart Study. Internal and Emergency Medicine, 2016, 11, 77-83.	1.0	13
231	Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 9-15.	1.5	13
232	Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies. BMC Cardiovascular Disorders, 2018, 18, 112.	0.7	13
233	May Measurement Month 2017: Results of 39 national blood pressure screening programmes. European Heart Journal Supplements, 2019, 21, D1-D4.	0.0	13
234	The Gut Microbiota and Vascular Aging: A State-of-the-Art and Systematic Review of the Literature. Journal of Clinical Medicine, 2022, 11, 3557.	1.0	13

#	Article	IF	CITATIONS
235	The Role of Irbesartan in the Treatment of Patients with Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 19-31.	1.0	12
236	Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. International Journal of Cardiology, 2013, 166, 210-214.	0.8	12
237	Inner ear symptoms: can we use them to approach cardiovascular diseases?. Internal and Emergency Medicine, 2014, 9, 825-827.	1.0	12
238	Clinical Management of Patients with Hypertension and High Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 107-117.	1.0	12
239	Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies. Journal of Cardiovascular Pharmacology. 2017. 69. 48-54.	0.8	12
240	Change gout: how to deal with this "silently-developing killer―in everyday clinical practice. Current Medical Research and Opinion, 2018, 34, 1411-1417.	0.9	12
241	Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study. European Journal of Preventive Cardiology, 2020, 27, 2251-2254.	0.8	12
242	The Complex Relationship Between Serum Uric Acid, Endothelial Function and Small Vessel Remodeling in Humans. Journal of Clinical Medicine, 2020, 9, 2027.	1.0	12
243	Uric acid and estimate of renal function. Let's stick together. International Journal of Cardiology, 2020, 310, 157-158.	0.8	12
244	Is the 2020 Sampson equation the best formula for LDL-C estimation?. European Journal of Internal Medicine, 2021, 83, 99-101.	1.0	12
245	Is tinnitus useful in early detection of incoming heart decompensation?. Medical Hypotheses, 2006, 67, 437-439.	0.8	11
246	Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. Atherosclerosis, 2014, 235, 81-83.	0.4	11
247	Hyperuricemia is associated with increased hospitalization risk and healthcare costs: Evidence from an administrative database in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 951-961.	1.1	11
248	A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension. Drugs, 2018, 78, 1783-1790.	4.9	11
249	Prospective meta-analysis protocol on randomised trials of renin–angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension. BMJ Open, 2021, 11, e043625.	0.8	11
250	Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 236-242.	1.4	11
251	Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management. Heart International, 2006, 2, 98.	0.4	11
252	Effect of Dietary Supplementation with Eufortyn® Colesterolo Plus on Serum Lipids, Endothelial Reactivity, Indexes of Non-Alcoholic Fatty Liver Disease and Systemic Inflammation in Healthy Subjects with Polygenic Hypercholesterolemia: The ANEMONE Study. Nutrients, 2022, 14, 2099.	1.7	11

#	Article	IF	CITATIONS
253	Gastric type proton pump of the inner ear: Its possible involvement in labyrinthine disorders. Audiological Medicine, 2008, 6, 249-250.	0.4	10
254	Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients. Nutrafoods, 2012, 11, 55-61.	0.5	10
255	Emerging biologic therapies for hypercholesterolaemia. Expert Opinion on Biological Therapy, 2017, 17, 1077-1087.	1.4	10
256	Prevalent Seasoning and Cooking Fats, Arterial Stiffness and Blood Lipid Pattern in a Rural Population Sample: Data from the Brisighella Heart Study. Nutrients, 2020, 12, 3063.	1.7	10
257	A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO®) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study). Nutrients, 2020, 12, 3127.	1.7	10
258	New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091380.	1.4	10
259	The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study. Reviews in Cardiovascular Medicine, 2021, 22, 991.	0.5	10
260	Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 557-567.	1.4	10
261	Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 633878.	1.1	10
262	Acute Kidney Injury in Pediatric Diabetic Kidney Disease. Frontiers in Pediatrics, 2021, 9, 668033.	0.9	10
263	Effects of Treatment with Zofenopril in Men and Women with Acute Myocardial Infarction: Gender Analysis of the SMILE Program. PLoS ONE, 2014, 9, e111558.	1.1	10
264	Long-Term Impact of Different Triple Combination Antihypertensive Medications on Blood Pressure Control, Metabolic Pattern and Incident Events: Data from the Brisighella Heart Study. Journal of Clinical Medicine, 2021, 10, 5921.	1.0	10
265	Clinical aspects of ACE inhibition in patients with acute myocardial infarction. Cardiovascular Drugs and Therapy, 1996, 10, 519-525.	1.3	9
266	A different modulation of vascular endothelial growth factor (VEGF) activation in response to hypoxia could cause different clinical pictures in inner ear disorders. Audiological Medicine, 2010, 8, 33-35.	0.4	9
267	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 73-102.	1.0	9
268	Effect of Zofenopril and Ramipril on Cardiovascular Mortality in Patients With Chronic Heart Failure. American Journal of Cardiology, 2013, 112, 90-93.	0.7	9
269	Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction. Journal of Hypertension, 2013, 31, 1256-1264.	0.3	9
270	Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart, 2015, 2, e000220.	0.9	9

#	Article	IF	CITATIONS
271	Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients. Journal of Human Hypertension, 2017, 31, 605-610.	1.0	9
272	Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population. International Journal of Molecular Sciences, 2018, 19, 49.	1.8	9
273	Angiotensin-Converting Enzyme Inhibition: Beyond Blood Pressure Control—The Role of Zofenopril. Advances in Therapy, 2020, 37, 4068-4085.	1.3	9
274	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. European Journal of Preventive Cardiology, 2022, 29, 1501-1509.	0.8	9
275	Sex hormones and adipokines in healthy pre-menopausal, post-menopausal and elderly women, and in age-matched men: data from the Brisighella Heart study. Journal of Endocrinological Investigation, 2011, 34, e158-62.	1.8	9
276	Dietary determinants of oxidized-low-density lipoprotein antibodies in a sample of pharmacologically untreated non-smoker subjects: data from the Brisighella heart study. Advances in Clinical and Experimental Medicine, 2013, 22, 69-76.	0.6	9
277	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 353-359.	1.0	9
278	Importance of Plasma Renin Activity Suppression and Venous Distensibility on Pressor and Natriuretic Responses to Intravenous Salt Load in Borderline Hypertension. American Journal of Hypertension, 1988, 1, 294-297.	1.0	8
279	Atrial Natriuretic Factor Modulates the Plasma Levels of a Na+/K+ ATPase Inhibitor in Volume Expanded Borderline Hypertensives. American Journal of Hypertension, 1991, 4, 618-622.	1.0	8
280	Tinnitus as a warning for preventing vasovagal syncope. Medical Hypotheses, 2009, 73, 370-371.	0.8	8
281	The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?. Expert Opinion on Pharmacotherapy, 2018, 19, 1853-1856.	0.9	8
282	Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients. Expert Opinion on Drug Safety, 2020, 19, 1577-1583.	1.0	8
283	Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials. Marine Drugs, 2020, 18, 292.	2.2	8
284	Can Lung Ultrasound be Used to Screen for Pulmonary Embolism in Patients with SARS-CoV-2 Pneumonia?. European Journal of Case Reports in Internal Medicine, 2019, 7, 001748.	0.2	8
285	Advanced diagnostic support in lipidology project: role for phenotypic and functional evaluation of lipoproteins in dyslipidemias. Clinical Lipidology, 2010, 5, 329-337.	0.4	7
286	Clinical Management of Hypertension in Pregnancy. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 123-127.	1.0	7
287	National Survey on Excellence Centers and Reference Centers for Hypertension Diagnosis and Treatment: Geographical Distribution, Medical Facilities and Diagnostic Opportunities. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 29-36.	1.0	7
288	Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire. Internal and Emergency Medicine, 2015, 10, 943-954.	1.0	7

#	Article	IF	CITATIONS
289	Primary vascular dysregulation syndrome: Possible implications for inner ear acute diseases?. Medical Hypotheses, 2015, 85, 586-587.	0.8	7
290	NoSAS score associated with arterial stiffness in a large cohort of healthy individuals. Lancet Respiratory Medicine,the, 2016, 4, e54.	5.2	7
291	Is it Possible to Significantly Modify Blood Pressure with a Combined Nutraceutical on Top of a Healthy Diet? The Results of a Pilot Clinical Trial. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 401-405.	1.0	7
292	Uric acid and early prevention of vascular diseases: Women under the looking glass. International Journal of Cardiology, 2018, 272, 314-315.	0.8	7
293	Serum uric acid and markers of low-density lipoprotein oxidation in nonsmoking healthy subjects: data from the Brisighella Heart Study. Polish Archives of Internal Medicine, 2014, 124, 661-668.	0.3	7
294	Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. American Heart Journal Plus, 2022, 13, 100127.	0.3	7
295	The Use of Zofenopril and Fosinopril in Acute Myocardial Infarction and Carotid Artery Disease. American Journal of Hypertension, 1994, 7, 96S-101S.	1.0	6
296	Is there a role for atrial peptides in the labyrinthine "disease�. Medical Hypotheses, 2006, 66, 1188-1190.	0.8	6
297	Detection of familial combined hyperlipoproteinaemia patients in the Brisighella Heart Study historical cohort: An epidemiological approach. Journal of Inherited Metabolic Disease, 2007, 30, 268-268.	1.7	6
298	Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statinâ€treated hypertensive hypercholesterolemic patients. Fundamental and Clinical Pharmacology, 2009, 23, 583-588.	1.0	6
299	Hypertension: management perspectives. Expert Opinion on Pharmacotherapy, 2012, 13, 1999-2003.	0.9	6
300	Zofenopril plus hydrochlorothiazide combination in the treatment of hypertension: an update. Expert Review of Cardiovascular Therapy, 2014, 12, 1055-1065.	0.6	6
301	Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey. Journal of Human Hypertension, 2015, 29, 409-416.	1.0	6
302	Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 205-209.	1.5	6
303	Cough and ACE Inhibitors: The Truth Beyond Placebo. Clinical Pharmacology and Therapeutics, 2019, 105, 550-552.	2.3	6
304	Glycoâ€metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). Diabetes/Metabolism Research and Reviews, 2020, 36, e3219.	1.7	6
305	Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study. Monaldi Archives for Chest Disease, 2021, 91, .	0.3	6
306	New evidences on the association between high-density lipoprotein cholesterol and cardiovascular risk: a never ending research story. European Journal of Preventive Cardiology, 2022, 29, 842-843.	0.8	6

#	Article	IF	CITATIONS
307	The treatment of hypertension in pregnancy. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 2002, 20, S52-6.	0.1	6
308	Efficacy and tolerability of a combined lipid-lowering nutraceutical on cholesterolemia, hs-CRP level and endothelial function in moderately hypercholesterolemic subjects. Journal of Biological Regulators and Homeostatic Agents, 2016, 30, 593-8.	0.7	6
309	Atrial Natriuretic Factor Response to Acute Volume Expansion in Borderline Hypertension. Role of Ace-Inhibition and Changes in Peripheral Venous Tone. Clinical and Experimental Hypertension, 1993, 15, 339-354.	0.5	5
310	A Risk-Benefit Assessment of ACE Inhibitor Therapy Post-Myocardial Infarction. Drug Safety, 1996, 14, 277-287.	1.4	5
311	Complementary and Alternative Medicine for Hypertension. Evidence - Based Integrative Medicine, 2005, 2, 47-55.	0.2	5
312	Omega-3 in Antiarrhythmic Therapy. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 207-211.	1.0	5
313	Combination therapy in the extended cardiovascular continuum. Journal of Cardiovascular Medicine, 2015, 16, 390-399.	0.6	5
314	Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome). Journal of Hypertension, 2016, 34, 2287-2297.	0.3	5
315	Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031665648.	1.0	5
316	New Opportunities for Monitoring Blood Pressure Control and Awareness in the Population: Insights from 12-Year Editions of the World Hypertension Day. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 333-335.	1.0	5
317	Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z―Studies. Advances in Therapy, 2017, 34, 784-798.	1.3	5
318	Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. Journal of Cardiovascular Pharmacology, 2017, 69, 298-304.	0.8	5
319	Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey. Clinical Hypertension, 2017, 23, 10.	0.7	5
320	Questioning the Associations of ω-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA Cardiology, 2018, 3, 780.	3.0	5
321	May Measurement Month 2018: results of blood pressure screening from 41 countries. European Heart Journal Supplements, 2020, 22, H1-H4.	0.0	5
322	Longitudinal trends in the prevalence of hyperuricaemia and chronic kidney disease in hypertensive and normotensive adults. Blood Pressure, 2020, 29, 308-318.	0.7	5
323	Uric acid and risk of myocardial infarction. A dynamic duo. International Journal of Cardiology, 2020, 320, 23-24.	0.8	5
324	Laboratory and Instrumental Risk Factors Associated with a Sudden Cardiac Death Prone ECG Pattern in the General Population: Data from the Brisighella Heart Study. Journal of Clinical Medicine, 2021, 10, 640.	1.0	5

#	Article	IF	CITATIONS
325	Diets, Foods and Food Components' Effect on Dyslipidemia. Nutrients, 2021, 13, 741.	1.7	5
326	The "Early Treatment―Approach Reducing Cardiovascular Risk in Patients with TypeÂ2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. Diabetes Therapy, 2021, 12, 1445-1461.	1.2	5
327	Projecting the long-term benefits of single pill combination therapy for patients with hypertension in five countries. International Journal of Cardiology Cardiovascular Risk and Prevention, 2021, 10, 200102.	0.4	5
328	Noninvasive instrumental evaluation of coenzyme <scp> Q ₁₀ </scp> phytosome on endothelial reactivity in healthy nonsmoking young volunteers: A doubleâ€blind, randomized, placebo ontrolled crossover clinical trial. BioFactors, 2022, , .	2.6	5
329	Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study. Biomedicines, 2022, 10, 656.	1.4	5
330	Peripheral Hemodynamic and Humoral Effects of Oral Zofenopril Calcium (SQ. 26,991) in Patients with Congestive Heart Failure. Journal of Clinical Pharmacology, 1989, 29, 1077-1082.	1.0	4
331	Blood Pressure Modulating Properties of Omega-3 Polyunsaturated Fatty Acids (PUFA). High Blood Pressure and Cardiovascular Prevention, 2007, 14, 55-61.	1.0	4
332	Drugs and tinnitus: A review of a controversial matter. Audiological Medicine, 2010, 8, 1-4.	0.4	4
333	Clinical management of patients with hypertension and high cardiovascular risk in specialised centers and in general practice. Analysis from an Italian Survey Questionnaire. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 866-874.	1.1	4
334	The influence of systemic circulation on hearing: The reliability of a different impact of microcirculatory defects and atherosclerosis. Medical Hypotheses, 2016, 91, 6-8.	0.8	4
335	New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation. Journal of Hypertension, 2017, 35, 689-695.	0.3	4
336	Efficacy of zofenopril in combination with amlodipine in patients with acute myocardial infarction: a pooled individual patient data analysis of four randomized, double-blind, controlled, prospective studies. Current Medical Research and Opinion, 2018, 34, 1869-1874.	0.9	4
337	Canrenone on cardiovascular mortality in congestive heart failure. Pharmacological Research, 2019, 141, 46-52.	3.1	4
338	Cost-effectiveness analysis of different hypertension management strategies. Internal and Emergency Medicine, 2020, 15, 181-182.	1.0	4
339	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2020, 22, H70-H73.	0.0	4
340	Short-Term Effect of a New Oral Sodium Hyaluronate Formulation on Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Diseases (Basel, Switzerland), 2020, 8, 26.	1.0	4
341	Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population?. Journal of Clinical Hypertension, 2020, 22, 897-905.	1.0	4
342	Hyperuricemia and mortality in heart failure: Is it time to change the route?. European Journal of Internal Medicine, 2020, 72, 40-41.	1.0	4

#	Article	IF	CITATIONS
343	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2021, 23, B77-B81.	0.0	4
344	Long-term consequences of previous preeclampsia and complicated pregnancy: analysis of echocardiographic aspects. Journal of Cardiovascular Medicine, 2021, 22, 939-945.	0.6	4
345	Association Between Aldosterone and Parathyroid Hormone Levels in Patients With Adrenocortical Tumors. Endocrine Practice, 2022, 28, 90-95.	1.1	4
346	Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. Vascular Health and Risk Management, 2006, 2, 341-349.	1.0	4
347	Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 815-826.	1.1	4
348	Socioeconomic status as determinant of individual cardiovascular risk. Atherosclerosis, 2022, 346, 82-83.	0.4	4
349	A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. Mediterranean Journal of Nutrition and Metabolism, 2008, 1, 33-36.	0.2	3
350	Omega-3 fatty acids: A promising possible treatment for Meniere's Disease and other inner ear disorders of unknown origin?. Medical Hypotheses, 2012, 79, 468-470.	0.8	3
351	Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4. ClinicoEconomics and Outcomes Research, 2013, 5, 317.	0.7	3
352	The possible role of Vicorder® apparatus in the diagnostic protocol of inner ear diseases. Hearing, Balance and Communication, 2015, 13, 175-177.	0.1	3
353	Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ejection fraction at entry. Open Heart, 2015, 2, e000195.	0.9	3
354	The cost–effectiveness of irbesartan for hypertension. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 199-207.	0.7	3
355	Cardiovascular risk factors and hearing impairment: a non-automatic correlation. Hearing, Balance and Communication, 2016, 14, 183-188.	0.1	3
356	Risk Factors for Lacunar Strokes with Visible Cerebral Lesions on Computed Tomography Scan. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1381-1388.	0.7	3
357	Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the <scp>SMILE</scp> â€4 Randomized, Doubleâ€Blind Study in Diabetic Patients. Cardiovascular Therapeutics, 2016. 34. 76-84.	1.1	3
358	Management of a Multicomorbid Patient with Heart Failure. Cardiology, 2017, 138, 21-23.	0.6	3
359	Serum Urate, Uricase, and Blood Pressure Control in Gout. Hypertension, 2019, 74, 23-25.	1.3	3
360	Successful treatment of a patient with mitochondrial myopathy with alirocumab. Journal of Clinical Lipidology, 2020, 14, 646-648.	0.6	3

#	Article	IF	CITATIONS
361	Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 346-351.	1.4	3
362	Uric acid and thrombotic risk: an emerging link. Internal and Emergency Medicine, 2020, 15, 1167-1168.	1.0	3
363	OUP accepted manuscript. European Heart Journal, 2021, 42, 4589-4591.	1.0	3
364	Evolving concept of cardioprotection in myocardial infarction: from SMILE-1 to SMILE-5. Kardiologia Polska, 2013, 71, 667-674.	0.3	3
365	Impact of serum uric acid levels on cardiovascular events and quality of life in patients with chronic coronary syndromes: Insights from a contemporary, prospective, nationwide registry. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 393-401.	1.1	3
366	Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 105-113.	1.0	3
367	Serum Malondialdehyde Levels in Hypertensive Patients: A Non-invasive Marker of Oxidative Stress. A Systematic Review and Meta-analysis. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 263-273.	1.0	3
368	Primary and Secondary Prevention of Myocardial Infarction. Clinical and Experimental Hypertension, 1996, 18, 547-558.	0.5	2
369	Hypertension: Quo Vadis?. Current Vascular Pharmacology, 2012, 10, 739-742.	0.8	2
370	Idiopathic sudden hearing loss: another kind of circulatory risk should not be neglected. European Archives of Oto-Rhino-Laryngology, 2013, 270, 2371-2372.	0.8	2
371	Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users. Hearing, Balance and Communication, 2014, 12, 84-87.	0.1	2
372	Gout and CV disease: It is time to move on. International Journal of Cardiology, 2018, 270, 311.	0.8	2
373	Diabetes in the third millennium: prognosis improves, but juvenile forms are more frequent. European Heart Journal Supplements, 2019, 21, B17-B18.	0.0	2
374	Severe hypercholesterolaemia in a paediatric patient with congenital analbuminaemia. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 316-317.	1.1	2
375	Severe impaired blood pressure control caused by baroreflex failure as a late sequela of neck irradiation. Journal of Hypertension, 2020, 38, 553-556.	0.3	2
376	Are monotherapies still valuable to the treatment of hypertension?. Expert Opinion on Pharmacotherapy, 2020, 21, 1523-1526.	0.9	2
377	Febuxostat and atrial fibrillation. European Heart Journal, 2020, 41, 2916-2917.	1.0	2
378	Reply to â€~The case for evidence-based medicine for the association between hyperuricaemia and CKD'. Nature Reviews Nephrology, 2020, 16, 422-423.	4.1	2

#	Article	IF	CITATIONS
379	Zofenopril: Blood pressure control and cardio-protection. Cardiology Journal, 2021, , .	0.5	2
380	Possible Advantages Deriving from Patiromer Use in Hypertensive Patients Made Hyperkalemic by Renin–Angiotensin–Aldosterone Blocking Agents. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 555-559.	1.0	2
381	From classical to innovative clinical epidemiology: the 50 years' experience of the Brisighella Heart Study. Panminerva Medica, 2021, 63, .	0.2	2
382	Low Dose of ACE-Inhibitor Enhances Sodium Excretion in Volume Expanded Patients with Borderline Hypertension. Blood Pressure, 1996, 5, 105-112.	0.7	1
383	Hypercholesterolemia and progression of high-normal blood pressure to hypertension. American Journal of Hypertension, 2003, 16, A207.	1.0	1
384	Compliance with therapy in hypertensive patients. Internal and Emergency Medicine, 2006, 1, 175-176.	1.0	1
385	Effects of Telmisartan and Bisoprolol on Blood Pressure, Peripheral Haemodynamic and Lipid Profile in Statin-Treated Hypertensive Hypercholesterolaemic Patients. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 7-12.	1.0	1
386	P3.07 OXYGEN CONSUMPTION KINETICS IN SUPRA-ANAEROBIC THRESHOLD CONSTANT LOAD EXERCISES ALLOW TO QUANTIFY IN TRAINED AND UNTRAINED SUBJECTS CYTOCHROME C-OXIDASE INHIBITION BY NITRIC OXIDE AND SHOW THIS DIRECT EFFECT AFTER NITRATE. Artery Research, 2010, 4, 160.	0.3	1
387	Cost effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post- hoc analysis of the smile-4 study. Value in Health, 2013, 16, A286-A287.	0.1	1
388	In response: Hyperuricemia as a risk factor for cardiovascular disease. Expert Review of Cardiovascular Therapy, 2015, 13, 21-22.	0.6	1
389	Subjective effects of a combined lipid-lowering nutraceutical or ezetimibe on well-being and sexual performance in patients with perceived worsening of erectile function during statin treatment: a randomised clinical trial. Nutrafoods, 2015, 14, 127-131.	0.5	1
390	Metabolic alterations and hearing acuity: lack of a significant clinical correlation. Hearing, Balance and Communication, 2016, 14, 91-93.	0.1	1
391	Hypertension in children: Knowledge is the road to prevention. Atherosclerosis, 2017, 259, 99-100.	0.4	1
392	Decrease mortality in type II diabetes mellitus. Journal of Cardiovascular Medicine, 2018, 19, e13-e15.	0.6	1
393	Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 355-359.	1.0	1
394	The UrgeRe (Urgenze Ipertensive: Un Progetto Educazionale Fondato Sulla Vita Reale, Hypertensive) Tj ETQq0 0 0 2021, 28, 151-157.) rgBT /O 1.0	verlock 10 Tf 1
395	Improving adherence with treatment-resistant hypertension. Expert Opinion on Pharmacotherapy, 2021, 22, 1373-1375.	0.9	1
396	Ill-being and well-being in patients with masked hypertension. Journal of Cardiovascular Medicine,	0.6	1

^{2021,} Publish Ahead of Print, e15-e17.

#	Article	IF	CITATIONS
397	The VO2-on Kinetics in Constant Load Exercise Sub-Anaerobic Threshold Reflects Endothelial Function and Dysfunction in Muscle Microcirculation. Physiological Research, 2015, 64, 807-819.	0.4	1
398	Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update. Cardiology Journal, 2019, 26, 99-101.	0.5	1
399	Factors associated with the development of stable hypertension in young borderline hypertensives. Journal of Hypertension, 1996, 14, 509-17.	0.3	1
400	Uric Acid, Genetic Scores and Renal Disease: Merge to Separate?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e4234-e4235.	1.8	1
401	Factors Associated with Acute Salt-Sensitivity in Borderline Hypertensive Patients. Clinical and Experimental Hypertension, 1992, 14, 837-851.	0.3	Ο
402	Effects of an integrated approach to care in the management of hypertensive patients with heart failure. American Journal of Hypertension, 2003, 16, A85-A86.	1.0	0
403	Cholesterol levels, plasma renin activity and incidence of stable hypertension in young subjects with high-normal blood pressure. American Journal of Hypertension, 2004, 17, S153.	1.0	Ο
404	Selective Peroxisome Proliferator-Activated Receptor-?? Modulation in the Treatment of Hypertension and Metabolic Syndrome. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 81-84.	1.0	0
405	Systemic haemodynamic profile and labyrinthine disorders. Audiological Medicine, 2006, 4, 58-59.	0.4	Ο
406	Left Atrial Volume is a Relevant Predictor of Cardiovascular Outcomes in Dialysis Patients. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
407	Quality of Life and Pulse Pressure in Elderly People: the Role of Physical Exercise. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	Ο
408	Patterns of Left Ventricular Hypertrophy in Hypertensives with Chronic Renal Insufficiency. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
409	2009 SIPREC Consensus Document – Executive Summary. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 237-247.	1.0	0
410	Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid-lowering properties: a randomized clinical trial. Mediterranean Journal of Nutrition and Metabolism, 2011, 4, 197-201.	0.2	0
411	Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid-lowering properties: a randomized clinical trial. Mediterranean Journal of Nutrition and Metabolism, 2011, 4, 197-201.	0.2	Ο
412	ls it possible to consider non-conventional proposals for treating Ménière's disease?. Audiological Medicine, 2012, 10, 182-185.	0.4	0
413	Ménière's disease: Is it time to approach it from another point of view?. Audiological Medicine, 2012, 10, 151-152.	0.4	0
414	A possible mechanism to explain how ischaemia and the maintained function of gastric type proton pumps could lead to hydrops of the inner ear in Ménière's disease. Hearing, Balance and Communication, 2013, 11, 3-5.	0.1	0

#	Article	IF	CITATIONS
415	Cardiovascular drugs and mortality in hypertensive patients with atrial fibrillation: evidence of efficacy for a global approach. Hypertension Research, 2014, 37, 492-493.	1.5	0
416	Is it time to implement a standardized oral glucose and fat load test to detect high risk patients? Probably not yet…. Atherosclerosis, 2015, 243, 346-347.	0.4	0
417	National Cross-Sectional Survey on Blood Pressure: A Gateway to a Better Appraisal of Hypertension in the Young. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 141-142.	1.0	0
418	Reply. American Journal of Obstetrics and Gynecology, 2016, 214, 414-415.	0.7	0
419	Cardioprotective role of zofenopril in hypertensive patients with acute myocardial infarction: a pooled individual data analysis of the SMILE studies. Blood Pressure, 2017, 26, 211-219.	0.7	Ο
420	Efficacy of Ace Inhibition with Zofenopril, Lisinopril, or Ramipril in Postacute Myocardial Infarction Patients With or Without Metabolic Syndrome: A Pooled Individual Data Analysis of Four Randomized, Double-Blind, Controlled, Prospective Studies. Metabolic Syndrome and Related Disorders, 2017, 15, 312-318	0.5	0
421	Letter by Cicero et al Regarding Article, "Long-Term Excessive Body Weight and Adult Left Ventricular Hypertrophy Are Linked Through Later-Life Body Size and Blood Pressure: The Bogalusa Heart Studyâ€, Circulation Research, 2017, 120, e50.	2.0	Ο
422	Reply to: Serum uric acid levels positively correlates with 10-year cardiovascular risk score in the general population from China. International Journal of Cardiology, 2018, 258, 298.	0.8	0
423	Letter by Borghi and Cicero Regarding Article, "Modifiable Risk Factors and Atrial Fibrillationâ€. Circulation, 2018, 137, 1532-1533.	1.6	0
424	Efficacy of zofenopril in combination with thiazide diuretics in patients with acute myocardial infarction: a pooled individual data analysis of four randomized, double-blind, controlled, prospective studies. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1185-1190.	0.9	0
425	Portrait of the Countess Anastasia Spini (1842): acromegaly in art. Hormones, 2019, 18, 517-518.	0.9	0
426	Efficacy of Zofenopril Alone or in Combination with Hydrochlorothiazide in Patients with Kidney Dysfunction. Current Clinical Pharmacology, 2019, 14, 5-15.	0.2	0
427	A meta-analysis of Italian and Estonian individuals shows an effect of common variants in HMGCR on blood apoB levels. Biomarkers in Medicine, 2019, 13, 931-940.	0.6	Ο
428	Nephrotic range proteinuria and acute heart failure. Internal and Emergency Medicine, 2020, 15, 105-108.	1.0	0
429	Dual RAAS inhibition and cardiorenal disease: is enough really enough?. Internal and Emergency Medicine, 2020, 15, 361-363.	1.0	0
430	Not all that trembles…: a rare case of extrapyramidal impairment. Internal and Emergency Medicine, 2021, 16, 729-733.	1.0	0
431	Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty. Medicina (Lithuania), 2021, 57, 857.	0.8	0
432	Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty. Medicina (Lithuania), 2021, 57, 857.	0.8	0

#	Article	IF	CITATIONS
433	Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. Mediterranean Journal of Nutrition and Metabolism, 2009, 3, 47-54.	0.2	Ο
434	VO2 Kinetics in Supra-Anaerobic Threshold Constant Tests Allow the Visualization and Quantification of the O2 Saving After Cytochrome C Oxidase Inhibition by Aerobic Training or Nitrate Administration. Physiological Research, 2013, 62, 671-679.	0.4	0
435	Serum Proinflammatory Chemokines in Healthy Elderly Taking or not Taking Simvastatin – Data from the Brisighella Heart Study. Advances in Clinical and Experimental Medicine, 2014, 23, 723-728.	0.6	Ο
436	Reply. Journal of Hypertension, 2020, 38, 2339-2340.	0.3	0
437	Determinants of acute salt sensitivity in hypertension-prone men. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 1991, 9, S318-9.	0.1	Ο
438	Relationship between acute suppression of plasma renin activity and lymphocyte Na+:H+ exchange rate in young patients with borderline hypertension. American Journal of the Medical Sciences, 1994, 307 Suppl 1, S159-62.	0.4	0
439	Effects of pharmacological modulation of the renin-angiotensin-aldosterone system on salt sensitivity in patients with borderline hypertension. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 1993, 11, S248-9.	0.1	Ο
440	4CPS-261â€Abstract withdrawn. , 2022, , .		0
441	1ISG-014â€Abstract withdrawn. , 2022, , .		Ο
442	Title is missing!. , 2020, 15, e0237297.		0
443	Title is missing!. , 2020, 15, e0237297.		Ο
444	Title is missing!. , 2020, 15, e0237297.		0
445	Title is missing!. , 2020, 15, e0237297.		Ο
446	Title is missing!. , 2020, 15, e0237297.		0
447	Title is missing!. , 2020, 15, e0237297.		0